Early approval of COVID-19 vaccines: Pros and cons

References

• Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science (80-). 1990;247(4949):1465–68. doi:10.1126/science.1690918.
   PubMed Web of Science ®Google Scholar
• Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines. 2019;7(2):37. doi:10.3390/vaccines7020037.
   PubMed Web of Science ®Google Scholar
• Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine. 1999;18(9–10):765–77. doi:10.1016/S0264-410X(99)00271-6.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines-a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79. doi:10.1038/nrd.2017.243.
   PubMed Web of Science ®Google Scholar
• Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci. 1995;772:30–39. doi:10.1111/j.1749-6632.1995.tb44729.x.
   PubMed Web of Science ®Google Scholar
• Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–40. doi:10.1038/mt.2008.200.
   PubMed Web of Science ®Google Scholar
• Kauffman KJ, Webber MJ, Anderson DG. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release. 2016;240:227–34. doi:10.1016/j.jconrel.2015.12.032.
   PubMed Web of Science ®Google Scholar
• Guan S, Rosenecker J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 2017;24(3):133–43. doi:10.1038/gt.2017.5.
   PubMed Web of Science ®Google Scholar
• #Vaccineswork. [accessed 2021 May 25]. https://www.gavi.org/vaccineswork?gclid=Cj0KCQjwna2FBhDPARIsACAEc_Xs53mjrz5yZ4vp5vpsxMqzGQhoWQ0jVVFlviYNGFfXMz8VkFpQ-74aAm-KEALw_wcB
   Google Scholar
• WHO. COVAX. 2020. [cited 2021 Mar 2]. https://www.who.int/initiatives/act-accelerator/covax
   Google Scholar
• WHO. COVID-19 vaccine doses shipped by the COVAX Facility head to Ghana, marking beginning of global rollout. 2021. [cited 2021 Mar 2]. https://www.who.int/news/item/24-02-2021-covid-19-vaccine-doses-shipped-by-the-covax-facility-head-to-ghana-marking-beginning-of-global-rollout
   Google Scholar
• Winsor M What is COVAX? How a global initiative is helping get COVID-19 vaccines to poorer countries. [accessed 2021 Mar 2]. https://abcnews.go.com/Health/covax-global-initiative-helping-covid-19-vaccines-poorer/story?id=76106981
   Google Scholar
• COVID live update: 167,986,676 cases and 3,487,062 deaths from the coronavirus – worldometer. 2021. [cited 2021 May 25]. https://www.worldometers.info/coronavirus/
   Google Scholar
• Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52. doi:10.1016/S0140-6736(20)30558-4.
   PubMed Web of Science ®Google Scholar
• Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, Sinn BV, Gerhold M, Hauptmann K, Ingold-Heppner B, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021;11(1):4263. doi:10.1038/s41598-021-82862-5.
   PubMed Web of Science ®Google Scholar
• Renu K, Prasanna PL, Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage – a review. Life Sci. 2020;255:117839. doi:10.1016/j.lfs.2020.117839.
   PubMed Web of Science ®Google Scholar
• Lee LA, Franzel L, Atwell J, Datta SD, Friberg IK, Goldie SJ, Reef SE, Schwalbe N, Simons E, Strebel PM, et al. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the gavi alliance. Vaccine. 2013;31:B61–72. doi:10.1016/j.vaccine.2012.11.035.
   PubMed Web of Science ®Google Scholar
• Hartmann G. Nucleic acid immunity. In: Alt FW, editor. Advances in immunology. New York, NY: Academic Press; 2017. p. 121–69.
   Google Scholar
• Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA. 2012;109(36):14604–09. doi:10.1073/pnas.1209367109.
   PubMed Web of Science ®Google Scholar
• Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, et al. A west Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis. 2007;196(12):1732–40. doi:10.1086/523650.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, Enama ME, Nelson S, Nason M, Gu W, et al. A west Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011;203(10):1396–404. doi:10.1093/infdis/jir054.
   PubMed Web of Science ®Google Scholar
• Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, et al. Safety and immunogenicity of DNA vaccines encoding ebolavirus and marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015;211(4):549–57. doi:10.1093/infdis/jiu511.
   PubMed Web of Science ®Google Scholar
• Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, Berkowitz N, Mendoza F, Saunders JG, Novik L, et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet. 2018;391(10120):552–62. doi:10.1016/S0140-6736(17)33105-7.
   PubMed Web of Science ®Google Scholar
• Kim TJ, Jin H-T, Hur S-Y, Yang HG, Seo YB, Hong SR, Lee C-W, Kim S, Woo J-W, Park KS, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5(1):1–14. doi:10.1038/ncomms6317.
   Google Scholar
• Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543(7644):248–51. doi:10.1038/nature21428.
   PubMed Web of Science ®Google Scholar
• Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Laska ME, Smith M, Almarsson Ö, Thompson J, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25(6):1316–27. doi:10.1016/j.ymthe.2017.03.035.
   PubMed Web of Science ®Google Scholar
• Schnee M, Vogel AB, Voss D, Petsch B, Baumhof P, Kramps T, Stitz L. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis. 2016;10(6):10. doi:10.1371/journal.pntd.0004746.
   Web of Science ®Google Scholar
• Chahal JS, Khan OF, Cooper CL, McPartlan JS, Tsosie JK, Tilley LD, Sidik SM, Lourido S, Langer R, Bavari S, et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci USA. 2016;113(29):E4133–42. doi:10.1073/pnas.1600299113.
   PubMed Web of Science ®Google Scholar
• Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. The Lancet. 2017;390(10101):1511–20. doi:10.1016/S0140-6736(17)31665-3.
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Routy J-P, Welles S, DeBenedette M, Tcherepanova I, Angel JB, Asmuth DM, Stein DK, Baril J-G, McKellar M, et al. Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016;72(1):31–38. doi:10.1097/QAI.0000000000000926.
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Kwon DS, Macklin EA, Shopis JR, McLean AP, McBrine N, Flynn T, Peter L, Sbrolla A, Kaufmann DE, et al. Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: results of a randomized, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016;71(3):246–53. doi:10.1097/QAI.0000000000000852.
   PubMed Web of Science ®Google Scholar
• Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74. doi:10.1016/S0140-6736(20)32623-4.
   PubMed Web of Science ®Google Scholar
• FDA. Moderna COVID-19 vaccine. 2021 [cited 2021 Feb 23]. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50. doi:10.1056/NEJMoa2027906.
   PubMed Web of Science ®Google Scholar
• Vaccines and related biological products advisory committee December 17, 2020 meeting briefing document - FDA. 2020;
   Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Eguia R, Crawford KHD, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2021;29(1):44–57.e9. doi:10.1016/j.chom.2020.11.007.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Castle JC, Türeci Ö, Sahin U. Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology. 2012;1(5):768–69. doi:10.4161/onci.19727.
   PubMed Web of Science ®Google Scholar
• Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012;30:1210–16. doi:10.1038/nbt.2436.
   PubMed Web of Science ®Google Scholar
• FDA. Pfizer-BioNTech COVID-19 Vaccine. 2021 [cited 2021 Feb 19]. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine
   Google Scholar
• WHO. WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out. 2021 [cited 2021 Mar 3]. https://www.who.int/news/item/15-02-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out
   Google Scholar
• Corbett K, Edwards D, Leist S, Abiona O, Boyoglu-Barnum S, Gillespie R, Himansu S, Schäfer A, Ziwawo C, DiPiazza A, et al. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness. bioRxiv Prepr Serv Biol. 2020;2020.06.11.145920.
   Google Scholar
• Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (80-). 2020;367(6483):1260–63. doi:10.1126/science.abb2507.
   PubMed Web of Science ®Google Scholar
• Van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J, Avanzato V, Bushmaker T, Flaxman A, Ulaszewska M, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv Prepr Serv Biol. 2020;2020.05.13.093195. [cited 2021 Mar 1]. 10.1101/2020.05.13.093195
   Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–78. doi:10.1016/S0140-6736(20)31604-4.
   PubMed Web of Science ®Google Scholar
• Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210(suppl 1):S380–9. doi:10.1093/infdis/jiu184.
   PubMed Web of Science ®Google Scholar
• Chaves M, Riccio P, Patrucco L, Rojas J, Cristiano E. Longitudinal myelitis associated with yellow fever vaccination. J Neurovirol. 2009;15(4):348–50. doi:10.1080/13550280903062805.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Aharon-Maor A, Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol. 2000;18:181–84.
   PubMed Web of Science ®Google Scholar
• Fleeton MN, Chen M, Berglund P, Rhodes G, Parker SE, Murphy M, Atkins GJ, Liljeström P. Self‐replicative RNA vaccines elicit protection against influenza a virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis. 2001;183(9):1395–98. doi:10.1086/319857.
   PubMed Web of Science ®Google Scholar
• Han S, Asoyan A, Rabenstein H, Nakano N, Obst R. Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc Natl Acad Sci USA. 2010;107(47):20453–58. doi:10.1073/pnas.1008437107.
   PubMed Web of Science ®Google Scholar
• Shin H, Wherry EJ. CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol. 2007;19(4):408–15. doi:10.1016/j.coi.2007.06.004.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Blattman JN, Murali-Krishna K, Van Der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77(8):4911–27. doi:10.1128/JVI.77.8.4911-4927.2003.
   PubMed Web of Science ®Google Scholar
• Edwards DK, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T, Fotin-Mleczek M, Petsch B, Wittman V. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J Transl Med. 2017;15(1):1. doi:10.1186/s12967-016-1111-6.
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol. 2005;23(1):307–36. doi:10.1146/annurev.immunol.23.021704.115843.
   PubMedGoogle Scholar
• Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu Y-J, Gilliet M. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med. 2005;202(1):135–43. doi:10.1084/jem.20050500.
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, Scarpa R. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19(5):102524. doi:10.1016/j.autrev.2020.102524.
   PubMed Web of Science ®Google Scholar
• White SM Could COVID-19 mRNA vaccines cause autoimmune diseases? 2020 [cited 2021 Mar 1]. https://www.bmj.com/content/371/bmj.m4347/rr-6
   Google Scholar
• Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA. 2007;104(15):6388–93. doi:10.1073/pnas.0608647104.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–101. doi:10.1056/NEJMoa2104840.
   PubMed Web of Science ®Google Scholar
• Hause AM, Gee J, Johnson T, Jazwa A, Marquez P, Miller E, Su J, Shimabukuro TT, Shay DK. Anxiety-related adverse event clusters after Janssen COVID-19 vaccination — five U.S. mass vaccination sites, April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):685–88. doi:10.15585/mmwr.mm7018e3.
   PubMed Web of Science ®Google Scholar
• See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP, Beavers SF, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021;325(24):2448. 10.1001/jama.2021.7517.
   PubMed Web of Science ®Google Scholar
• Singh Malhotra H, Gupta P, Prabhu V, Garg RK, Dandu H, Agarwal V. COVID-19 vaccination-associated myelitis. QJM An Int J Med. 2021;2021:1–3.
   Google Scholar
• Goss AL, Samudralwar RD, Das RR, Nath A. ANA investigates: neurological complications of COVID-19 vaccines. Ann Neurol. 2021;89(5):856–57. doi:10.1002/ana.26065.
   PubMed Web of Science ®Google Scholar
• Menaka P, Schull M, Razak F, Grill A, Ivers N, Maltsev A, Miller KJ, Schwartz B, Stall NM, Steiner R, et al. Vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) following AstraZeneca COVID-19 vaccination: interim guidance for healthcare professionals in emergency department and inpatient settings. 2021.
   Google Scholar
• Pottegård A, Lund LC, Ø K, Dahl J, Andersen M, Hallas J, Lidegaard Ø, Tapia G, Gulseth HL, Ruiz PL-D, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114. doi:10.1136/bmj.n1114.
   PubMed Web of Science ®Google Scholar
• Coronavirus vaccine - weekly summary of Yellow Card reporting - GOV.UK. 2021. [cited 2021 May 12]. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
   Google Scholar
• COVID-19 vaccine weekly safety report - 06-05-2021 | therapeutic Goods Administration (TGA). 2021. [cited 2021 May 12]. https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-06-05-2021
   Google Scholar
• COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets | European medicines agency. 2021. [cited 2021 Apr 5]. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots
   Google Scholar
• Gorse GJ, Patel GB, Vitale JN, O’Connor TZ. Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum. Clin Vaccine Immunol. 2010;17(12):1875–80. doi:10.1128/CVI.00278-10.
   PubMedGoogle Scholar
• Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity. 2020;53(2):248–63. doi:10.1016/j.immuni.2020.07.005.
   PubMed Web of Science ®Google Scholar
• Bradburne AF, Bynoe ML, Tyrrell DAJ. Effects of a “New” human respiratory virus in volunteers. Br Med J. 1967;3(5568):767–69. doi:10.1136/bmj.3.5568.767.
   PubMed Web of Science ®Google Scholar
• Callow KA, Parry HF, Sergeant M, Tyrrell DAJ. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105(2):435–46. doi:10.1017/S0950268800048019.
   PubMed Web of Science ®Google Scholar
• Hendley JO, Fishburne HB, Gwaltney JM. Coronavirus infections in working adults. Eight-year study with 229 E and OC 43. Am Rev Respir Dis. 1972;105(5):805–11. doi:10.1164/arrd.1972.105.5.805.
   PubMedGoogle Scholar
• Monto AS, Lim SK. The Tecumseh study of respiratory illness. VI. Frequency of and relationship between outbreaks of coronavirus infection. J Infect Dis. 1974;129(3):271–76. doi:10.1093/infdis/129.3.271.
   PubMed Web of Science ®Google Scholar
• Schmidt OW, Allan ID, Cooney MK, Foy HM, Fox JP. Rises in titers of antibody to human corona viruses oc43 and 229e in Seattle families during 1975-1979. Am J Epidemiol. 1986;123(5):862–68. doi:10.1093/oxfordjournals.aje.a114315.
   PubMed Web of Science ®Google Scholar
• Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, DeVincenzo JP, De Haan CAM, Wrammert J, Openshaw PJM, Chiu C. Impaired antibody-mediated protection and defective iga b-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med. 2015;191(9):1040–49. doi:10.1164/rccm.201412-2256OC.
   PubMed Web of Science ®Google Scholar
• Liu WM, Van Der Zeijst BAM, Boog CJP, Soethout EC. Aging and impaired immunity to influenza viruses: implications for vaccine development. Hum Vaccin. 2011;7(sup1):94–98. doi:10.4161/hv.7.0.14568.
   PubMed Web of Science ®Google Scholar
• Gr M. Developing a vaccine for human rhinoviruses. J Vaccines Immun. 2014;2(3):16–20. doi:10.14312/2053-1273.2014-3.
   PubMedGoogle Scholar
• Glanville N, Johnston SL. Challenges in developing a cross-serotype rhinovirus vaccine. Curr Opin Virol. 2015;11:83–88. doi:10.1016/j.coviro.2015.03.004.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MC, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–2383.e9. 10.1016/j.cell.2021.03.013.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021; 593:1–9.
   Web of Science ®Google Scholar
• McCallum M, Bassi J, De Marco A, Chen A, Walls AC, Di Iulio J, Alejandra Tortorici M, Navarro M-J, Silacci-Fregni C, Agostini M, et al. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv. 2021;2021.03.31.437925. doi:10.1101/2021.03.31.437925
   Google Scholar
• Frasca D, Riley RL, Blomberg BB. Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin Immunol. 2005;17(5):378–84. doi:10.1016/j.smim.2005.05.005.
   PubMed Web of Science ®Google Scholar
• Han S, Yang K, Ozen Z, Peng W, Marinova E, Kelsoe G, Zheng B. Enhanced differentiation of splenic plasma cells but diminished long-lived high-affinity bone marrow plasma cells in aged mice. J Immunol. 2003;170(3):1267–73. doi:10.4049/jimmunol.170.3.1267.
   PubMed Web of Science ®Google Scholar
• Naylor K, Li G, Vallejo AN, Lee -W-W, Koetz K, Bryl E, Witkowski J, Fulbright J, Weyand CM, Goronzy JJ. The influence of age on T cell generation and TCR diversity. J Immunol. 2005;174(11):7446–52. doi:10.4049/jimmunol.174.11.7446.
   PubMed Web of Science ®Google Scholar
• Cicin-Sain L, Smyk-Paerson S, Currier N, Byrd L, Koudelka C, Robinson T, Swarbrick G, Tackitt S, Legasse A, Fischer M, et al. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates. J Immunol. 2010;184(12):6739–45. doi:10.4049/jimmunol.0904193.
   PubMed Web of Science ®Google Scholar
• Yager EJ, Ahmed M, Lanzer K, Randall TD, Woodland DL, Blackman MA. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med. 2008;205(3):711–23. doi:10.1084/jem.20071140.
   PubMed Web of Science ®Google Scholar
• Effros RB, Boucher N, Porter V, Zhu X, Spaulding C, Walford RL, Kronenberg M, Cohen D, Schächter F. Decline in CD28+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol. 1994;29(6):601–09. doi:10.1016/0531-5565(94)90073-6.
   PubMed Web of Science ®Google Scholar
• Ahrenfeldt LJ, Otavova M, Christensen K, Lindahl-Jacobsen R. Sex and age differences in COVID-19 mortality in Europe. Wien Klin Wochenschr. 2020;133:1–6.
   Web of Science ®Google Scholar
• Kang SJ, Jung SI. Age-related morbidity and mortality among patients with COVID-19. Infect Chemother. 2020;52(2):154–64. doi:10.3947/ic.2020.52.2.154.
   PubMed Web of Science ®Google Scholar
• Undurraga EA, Chowell G, Mizumoto K. COVID-19 case fatality risk by age and gender in a high testing setting in Latin America: chile, March–August 2020. Infect Dis Poverty. 2021;10(1):11. doi:10.1186/s40249-020-00785-1.
   PubMed Web of Science ®Google Scholar
• Yanez ND, Weiss NS, Romand J-A, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health. 2020;20(1):1742. doi:10.1186/s12889-020-09826-8.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:NEJMoa2101765.
   PubMedGoogle Scholar
• Bernal JL, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, Simmons R, Cottrell S, Roberts R, O’Doherty M, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv. 2021;2021.03.01.21252652. 10.1101/2021.03.01.21252652
   Google Scholar
• Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, Heath R, Turner A, Friedrich Z, Morrison L, et al. Assessing the effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 vaccination in prevention of hospitalisations in elderly and frail adults: a single centre test negative case-control study. SSRN Electron J. 2021. doi:10.2139/ssrn.3796835.
   Google Scholar
• Nie Y, Wang -Y-Y. Innate immune responses to DNA viruses. Protein Cell. 2013;4(1):1–7. doi:10.1007/s13238-012-2122-6.
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441(7089):101–05. doi:10.1038/nature04734.
   PubMed Web of Science ®Google Scholar
• Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, Coch C, Janke M, Mihailovic A, Wardle G, et al. Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity. 2009;31(1):25–34. doi:10.1016/j.immuni.2009.05.008.
   PubMed Web of Science ®Google Scholar
• Liu G, Zhou Y, Tsai B. Cytoplasm and beyond: dynamic innate immune sensing of influenza a virus by RIG-I. J Virol. 2019;93(8):2299–317. doi:10.1128/JVI.02299-18.
   Web of Science ®Google Scholar
• Schlee M. Master sensors of pathogenic RNA – RIG-I like receptors. Immunobiology. 2013;218(11):1322–35. doi:10.1016/j.imbio.2013.06.007.
   PubMed Web of Science ®Google Scholar
• Davis WG, Bowzard JB, Sharma SD, Wiens ME, Ranjan P, Gangappa S, Stuchlik O, Pohl J, Donis RO, Katz JM, et al. The 3′ untranslated regions of influenza genomic sequences are 5′PPP-independent ligands for RIG-i. PLoS One. 2012;7(3):e32661. doi:10.1371/journal.pone.0032661.
   PubMed Web of Science ®Google Scholar
• Bowzard JB, Ranjan P, Sambhara S. RIG-I goes beyond naked recognition. Cell Host Microbe. 2013;13(3):247–49. doi:10.1016/j.chom.2013.02.012.
   PubMed Web of Science ®Google Scholar
• Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann -K-K, Schlee M, et al. 5’-triphosphate RNA is the ligand for RIG-I. Science (80-). 2006;314(5801):994–97. doi:10.1126/science.1132505.
   PubMed Web of Science ®Google Scholar
• Gorini S, Gatta L, Pontecorvo L, Vitiello L, la Sala A. Regulation of innate immunity by extracellular nucleotides. Am J Blood Res. 2013;3:14–28.
   PubMedGoogle Scholar
• Gil A. Modulation of the immune response mediated by dietary nucleotides. Eur J Clin Nutr. 2002;56(S3):S1–4. doi:10.1038/sj.ejcn.1601475.
   PubMedGoogle Scholar
• Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization: a field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969;89(4):435–48. doi:10.1093/oxfordjournals.aje.a120956.
   PubMed Web of Science ®Google Scholar
• Smatti MK, Al Thani AA, Yassine HM. Viral-induced enhanced disease illness. Front Microbiol. 2018;9:2991. doi:10.3389/fmicb.2018.02991.
   PubMed Web of Science ®Google Scholar
• Martin DB. Atypical measles in adolescents and young adults. Ann Intern Med. 1979;90(6):877–81. doi:10.7326/0003-4819-90-6-877.
   PubMed Web of Science ®Google Scholar
• Davis BS, Chang GJJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, Bowen R, Bunning ML. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol. 2001;75(9):4040–47. doi:10.1128/JVI.75.9.4040-4047.2001.
   PubMed Web of Science ®Google Scholar
• Garver KA, LaPatra SE, Kurath G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis Aquat Organ. 2005;64:13–22. doi:10.3354/dao064013.
   PubMed Web of Science ®Google Scholar
• The global race to vaccinate – foreign policy. 2021. [cited 2021 Apr 6]. https://foreignpolicy.com/2021/03/29/covid-19-vaccine-diplomacy-global-pandemic-response/
   Google Scholar